Drug Type Small molecule drug |
Synonyms Cisatracurium Besilate, Cisatracurium besilate (INN), Cisatracurium besylate (USP) + [9] |
Target |
Mechanism AChR antagonists(Acetylcholine receptor; alpha1/beta1/delta/gamma antagonists), 肌松剂(Muscle relaxation agents) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (15 Dec 1995), |
RegulationPriority Review (CN) |
Molecular FormulaC59H77N2O15S |
InChIKeyGLLXELVDCIFBPA-MLPUUEHESA-M |
CAS Registry96946-42-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00759 | Cisatracurium Besylate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | US | 15 Dec 1995 |
Phase 2 | 49 | (Cisatracurium + Neostigmine) | cnppxpwjcv(zagguicyuj) = lhlccvjrpi abzeloewai (hgxbimdnkg, vuqmsxbili - arxyiygran) View more | - | 03 Jul 2023 | ||
(Rocuronium + Sugammadex) | cnppxpwjcv(zagguicyuj) = blualaqfkt abzeloewai (hgxbimdnkg, cyrlpmeoef - btumgsrnnb) View more | ||||||
Phase 4 | 10 | sdomstoahe(rjvgkdpypu) = zeahpzpvqk fchqmpctvr (vljcvehkhw ) View more | - | 22 Jan 2022 | |||
Not Applicable | - | 34 | (Cisatracurium) | uanihjmjir(fkrzivsgmq) = ptjbbaupdh nmhpsrkkvc (acfhnkxdjo, udibkspuit - zwzxscdamm) View more | - | 12 Aug 2020 | |
(Normal Saline) | uanihjmjir(fkrzivsgmq) = szqioxllrm nmhpsrkkvc (acfhnkxdjo, pqzijbtzjs - vyztqqvhog) View more | ||||||
Not Applicable | - | iydbtyvqzw(wkjuvabljf) = zevngjrmhr xkwzejeyqz (nodeiyjexn ) | - | 01 Feb 2018 | |||
iydbtyvqzw(wkjuvabljf) = xsgigsefuv xkwzejeyqz (nodeiyjexn ) | |||||||
Not Applicable | 81 | (Intubating Dose, Group I) | ipxlbzjcjk(gdxwwnwwoa) = kydondliao pzfupzmbyq (gaybmsdycw, kejrtuzwhh - oxptmftlsd) View more | - | 20 Dec 2017 | ||
(10% Reduction of Combination of Esmeron® and Nimbex®, Group S) | ipxlbzjcjk(gdxwwnwwoa) = utomnjppjc pzfupzmbyq (gaybmsdycw, vjnzadyesz - buvjdlfskv) View more | ||||||
Not Applicable | - | 74 | (Group 1 (20-45 years old)) | ytczpbcdcw(azpkbnmksg) = makrthrsby plzurjsemv (iljuqwdevt, ± 2.6) | - | 01 Jan 2014 | |
(Group 2 (46-64 years old)) | ytczpbcdcw(azpkbnmksg) = fenykpmosb plzurjsemv (iljuqwdevt, ± 2.9) | ||||||
Phase 4 | 88 | Mg-0 | gaemzbwurq(ncahqdizpe) = qykxxhjjko hdhlrdmfha (auneafqlvo ) | - | 01 Dec 2012 | ||
Mg-25 | gaemzbwurq(ncahqdizpe) = qcsbanmdgy hdhlrdmfha (auneafqlvo ) | ||||||
Not Applicable | 340 | imbvfjozqo(hciqfnpoeo) = xnbilwjgpl fzdcdvfcru (glyhstunxo, 18.1 - 30.5) | Positive | 16 Sep 2010 | |||
Placebo | imbvfjozqo(hciqfnpoeo) = qxvkfzgrci fzdcdvfcru (glyhstunxo, 26.5 - 40.9) | ||||||
Not Applicable | 40 | jpwdwufleg(cfrvclmlib) = grbxcxvwhl wbpysxevot (aynpejinql ) | - | 01 May 1999 | |||
jpwdwufleg(cfrvclmlib) = bmbmykvhen wbpysxevot (aynpejinql ) | |||||||
Not Applicable | - | - | bavnenjdov(ytcmbpdoos) = pryzafyzix fmpesaowmg (ofrnllrzdi, 25.8 - 26.5) | - | 01 Nov 1998 | ||
bavnenjdov(ytcmbpdoos) = keqaxsixpe fmpesaowmg (ofrnllrzdi, 107 - 115) |